TY - JOUR
T1 - Childhood Lymphomatoid Granulomatosis: A Report of 2 Cases and Review of the Literature
AU - Tacke, Z.C.A.
AU - Eikelenboom, M.J.
AU - Vermeulen, R.J.
AU - van der Knaap, M.S.
AU - Euser, A.M.
AU - van der Valk, P.
AU - Kaspers, G.J.L.
PY - 2014
Y1 - 2014
N2 - Lymphomatoid granulomatosis (LG) is a B-cell type lymphoproliferative disease. It mainly affects the lungs but may have extrapulmonary manifestations, especially in the central nervous system. The purpose of this study was to review the pediatric cases in the literature and add 2 new cases to the existing literature. A review of the literature was performed on children (0 to 18 years of age at diagnosis) with pathologically proven LG. We found 47 case reports, which, together with 2 new cases, were systematically analyzed. The median age was 12 years. The main symptoms were general, pulmonary, and neurological. Approximately one third of the patients were immunocompromised. High mortality rate was observed. Pediatric LG is a rare disease, which appears to be more frequently seen in immunocompromised patients, especially patients with leukemia. The disease has a high mortality rate; therefore, aggressive therapy according to a high-grade B-cell lymphoma protocol is justified
AB - Lymphomatoid granulomatosis (LG) is a B-cell type lymphoproliferative disease. It mainly affects the lungs but may have extrapulmonary manifestations, especially in the central nervous system. The purpose of this study was to review the pediatric cases in the literature and add 2 new cases to the existing literature. A review of the literature was performed on children (0 to 18 years of age at diagnosis) with pathologically proven LG. We found 47 case reports, which, together with 2 new cases, were systematically analyzed. The median age was 12 years. The main symptoms were general, pulmonary, and neurological. Approximately one third of the patients were immunocompromised. High mortality rate was observed. Pediatric LG is a rare disease, which appears to be more frequently seen in immunocompromised patients, especially patients with leukemia. The disease has a high mortality rate; therefore, aggressive therapy according to a high-grade B-cell lymphoma protocol is justified
U2 - https://doi.org/10.1097/MPH.0000000000000090
DO - https://doi.org/10.1097/MPH.0000000000000090
M3 - Article
C2 - 24390446
SN - 1077-4114
VL - 36
SP - E416-E422
JO - Journal of Pediatric Hematology / Oncology
JF - Journal of Pediatric Hematology / Oncology
IS - 7
ER -
